全文获取类型
收费全文 | 280329篇 |
免费 | 35939篇 |
国内免费 | 2686篇 |
专业分类
耳鼻咽喉 | 7181篇 |
儿科学 | 9399篇 |
妇产科学 | 5181篇 |
基础医学 | 20793篇 |
口腔科学 | 6022篇 |
临床医学 | 34386篇 |
内科学 | 79113篇 |
皮肤病学 | 11370篇 |
神经病学 | 24781篇 |
特种医学 | 9251篇 |
外国民族医学 | 1篇 |
外科学 | 56724篇 |
综合类 | 941篇 |
现状与发展 | 72篇 |
一般理论 | 39篇 |
预防医学 | 19799篇 |
眼科学 | 6203篇 |
药学 | 9859篇 |
中国医学 | 647篇 |
肿瘤学 | 17192篇 |
出版年
2024年 | 748篇 |
2023年 | 5494篇 |
2022年 | 1796篇 |
2021年 | 5723篇 |
2020年 | 7240篇 |
2019年 | 5099篇 |
2018年 | 12267篇 |
2017年 | 10107篇 |
2016年 | 10960篇 |
2015年 | 11310篇 |
2014年 | 18821篇 |
2013年 | 20756篇 |
2012年 | 14754篇 |
2011年 | 15406篇 |
2010年 | 15250篇 |
2009年 | 17654篇 |
2008年 | 13684篇 |
2007年 | 12520篇 |
2006年 | 14278篇 |
2005年 | 11559篇 |
2004年 | 9954篇 |
2003年 | 8526篇 |
2002年 | 8196篇 |
2001年 | 7692篇 |
2000年 | 7507篇 |
1999年 | 6561篇 |
1998年 | 4194篇 |
1997年 | 3809篇 |
1996年 | 3690篇 |
1995年 | 3475篇 |
1994年 | 2157篇 |
1993年 | 1759篇 |
1992年 | 2674篇 |
1991年 | 2489篇 |
1990年 | 2009篇 |
1989年 | 1963篇 |
1988年 | 1673篇 |
1987年 | 1496篇 |
1986年 | 1523篇 |
1985年 | 1261篇 |
1984年 | 952篇 |
1983年 | 833篇 |
1982年 | 657篇 |
1979年 | 650篇 |
1977年 | 611篇 |
1975年 | 560篇 |
1974年 | 553篇 |
1973年 | 593篇 |
1972年 | 600篇 |
1970年 | 551篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
11.
12.
13.
14.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
15.
16.
17.
18.
Melatonin reduces oxidative stress and improves vascular function in pulmonary hypertensive newborn sheep 下载免费PDF全文
Flavio Torres Alejandro González‐Candia Camilo Montt Germán Ebensperger Magdalena Chubretovic María Serón‐Ferré Roberto V. Reyes Aníbal J. Llanos Emilio A. Herrera 《Journal of pineal research》2015,58(3):362-373
Pulmonary hypertension of the newborn (PHN) constitutes a critical condition with severe cardiovascular and neurological consequences. One of its main causes is hypoxia during gestation, and thus, it is a public health concern in populations living above 2500 m. Although some mechanisms are recognized, the pathophysiological facts that lead to PHN are not fully understood, which explains the lack of an effective treatment. Oxidative stress is one of the proposed mechanisms inducing pulmonary vascular dysfunction and PHN. Therefore, we assessed whether melatonin, a potent antioxidant, improves pulmonary vascular function. Twelve newborn sheep were gestated, born, and raised at 3600 meters. At 3 days old, lambs were catheterized and daily cardiovascular measurements were recorded. Lambs were divided into two groups, one received daily vehicle as control and another received daily melatonin (1 mg/kg/d), for 8 days. At 11 days old, lung tissue and small pulmonary arteries (SPA) were collected. Melatonin decreased pulmonary pressure and resistance for the first 3 days of treatment. Further, melatonin significantly improved the vasodilator function of SPA, enhancing the endothelial‐ and muscular‐dependent pathways. This was associated with an enhanced nitric oxide‐dependent and nitric oxide independent vasodilator components and with increased nitric oxide bioavailability in lung tissue. Further, melatonin reduced the pulmonary oxidative stress markers and increased enzymatic and nonenzymatic antioxidant capacity. Finally, these effects were associated with an increase of lumen diameter and a mild decrease in the wall of the pulmonary arteries. These outcomes support the use of melatonin as an adjuvant in the treatment for PHN. 相似文献
19.
Megan L. Robbins Robert C. Wright Ana María López Karen Weihs 《Journal of psychosocial oncology》2019,37(2):160-177
AbstractObjectives: This study examined word use as an indicator of interpersonal positive reframing in daily conversations of couples coping with breast cancer and as a predictor of stress.Design: The Electronically Activated Recorder (EAR) and Linguistic Inquiry and Word Count (LIWC) were used to examine naturally occurring word use conceptually linked to positive reframing (positive emotion, negative emotion, and cognitive processing words).Sample: Fifty-two couples coping with breast cancer.Methods: Couples wore the EAR, a device participants wear, that audio-recorded over one weekend (>16,000 sound files), and completed self-reports of positive reframing (COPE) and stress (Perceived Stress Scale). LIWC, a software program, measured word use.Findings: Both partners’ word use (i.e., positive emotion and cognitive processing words) was associated with their own reported positive reframing, and spouses’ word use was also indicative of patients’ positive reframing. Results also revealed that, in general, words indicating positive reframing predicted lower levels of stress.Conclusions: Findings supported the hypothesis that partners—and particularly spouses of breast cancer patients—may assist each other’s coping by positively reframing the cancer experience and other negative experiences in conversation. 相似文献
20.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.